234 related articles for article (PubMed ID: 16622189)
21. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
Tsujisawa T; Inoue H; Nishihara T
J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
[TBL] [Abstract][Full Text] [Related]
22. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis.
Zhang Z; Jimi E; Bothwell AL
J Immunol; 2003 Oct; 171(7):3620-6. PubMed ID: 14500659
[TBL] [Abstract][Full Text] [Related]
23. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
[TBL] [Abstract][Full Text] [Related]
24. Hemoglobin receptor protein from Porphyromonas gingivalis induces interleukin-8 production in human gingival epithelial cells through stimulation of the mitogen-activated protein kinase and NF-κB signal transduction pathways.
Fujita Y; Nakayama M; Naito M; Yamachika E; Inoue T; Nakayama K; Iida S; Ohara N
Infect Immun; 2014 Jan; 82(1):202-11. PubMed ID: 24126532
[TBL] [Abstract][Full Text] [Related]
25. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
Takayanagi H; Ogasawara K; Hida S; Chiba T; Murata S; Sato K; Takaoka A; Yokochi T; Oda H; Tanaka K; Nakamura K; Taniguchi T
Nature; 2000 Nov; 408(6812):600-5. PubMed ID: 11117749
[TBL] [Abstract][Full Text] [Related]
26. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
27. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.
Huh JE; Jung IT; Choi J; Baek YH; Lee JD; Park DS; Choi DY
Eur J Pharmacol; 2013 Jan; 698(1-3):57-66. PubMed ID: 22985747
[TBL] [Abstract][Full Text] [Related]
28. Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis.
Saito K; Ohara N; Hotokezaka H; Fukumoto S; Yuasa K; Naito M; Fujiwara T; Nakayama K
J Biol Chem; 2004 Apr; 279(14):13555-63. PubMed ID: 14729681
[TBL] [Abstract][Full Text] [Related]
29. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
30. Receptor activator of NF-kappaB ligand-stimulated osteoclastogenesis in mouse marrow culture is suppressed by zinc in vitro.
Yamaguchi M; Uchiyama S
Int J Mol Med; 2004 Jul; 14(1):81-5. PubMed ID: 15202020
[TBL] [Abstract][Full Text] [Related]
31. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling.
Wei S; Wang MW; Teitelbaum SL; Ross FP
J Biol Chem; 2002 Feb; 277(8):6622-30. PubMed ID: 11719504
[TBL] [Abstract][Full Text] [Related]
33. RelB-induced expression of Cot, an MAP3K family member, rescues RANKL-induced osteoclastogenesis in alymphoplasia mice by promoting NF-κB2 processing by IKKα.
Taniguchi R; Fukushima H; Osawa K; Maruyama T; Yasuda H; Weih F; Doi T; Maki K; Jimi E
J Biol Chem; 2014 Mar; 289(11):7349-61. PubMed ID: 24488495
[TBL] [Abstract][Full Text] [Related]
34. Porphyromonas gingivalis induces receptor activator of NF-kappaB ligand expression in osteoblasts through the activator protein 1 pathway.
Okahashi N; Inaba H; Nakagawa I; Yamamura T; Kuboniwa M; Nakayama K; Hamada S; Amano A
Infect Immun; 2004 Mar; 72(3):1706-14. PubMed ID: 14977979
[TBL] [Abstract][Full Text] [Related]
35. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
36. CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-kappaB-dependent, CD40-mediated bone destruction in rheumatoid arthritis.
Lee HY; Jeon HS; Song EK; Han MK; Park SI; Lee SI; Yun HJ; Kim JR; Kim JS; Lee YC; Kim SI; Kim HR; Choi JY; Kang I; Kim HY; Yoo WH
Arthritis Rheum; 2006 Jun; 54(6):1747-58. PubMed ID: 16736517
[TBL] [Abstract][Full Text] [Related]
37. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
[TBL] [Abstract][Full Text] [Related]
38. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation.
Ichikawa H; Aggarwal BB
Clin Cancer Res; 2006 Jan; 12(2):662-8. PubMed ID: 16428513
[TBL] [Abstract][Full Text] [Related]
39. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
Song J; Jing Z; Hu W; Yu J; Cui X
Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
[TBL] [Abstract][Full Text] [Related]
40. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.
Hayashi S; Yamada T; Tsuneto M; Yamane T; Takahashi M; Shultz LD; Yamazaki H
J Immunol; 2003 Nov; 171(10):5130-9. PubMed ID: 14607912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
